Abstract
In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1952-1957 |
| Number of pages | 6 |
| Journal | Blood |
| Volume | 83 |
| Issue number | 7 |
| State | Published - Apr 1 1994 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. / Mitus, A. Jacqueline; Antin, Joseph H.; Rutherford, Cynthia J.; McGarigle, Carol J.; Goldberg, Mark A.
In: Blood, Vol. 83, No. 7, 01.04.1994, p. 1952-1957.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs
AU - Mitus, A. Jacqueline
AU - Antin, Joseph H.
AU - Rutherford, Cynthia J.
AU - McGarigle, Carol J.
AU - Goldberg, Mark A.
PY - 1994/4/1
Y1 - 1994/4/1
N2 - In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.
AB - In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.
UR - http://www.scopus.com/inward/record.url?scp=0028350481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028350481&partnerID=8YFLogxK
M3 - Article
C2 - 8142661
AN - SCOPUS:0028350481
VL - 83
SP - 1952
EP - 1957
JO - Blood
JF - Blood
SN - 0006-4971
IS - 7
ER -